Management of the blood glucose abnormalities in HIV-infected patients

HIV and AIDS Review

Volumn 5, Issue 4, 2006, Pages 25-27

  Leszczyszyn Pynka, Magdalena ^a   Pynka, Sławomir ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; ANTIHYPERTENSIVE AGENT; ANTIRETROVIRUS AGENT; CHOLESTEROL; GLITAZONE DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEGLITINIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL;

BLOOD PRESSURE MONITORING; CLINICAL FEATURE; DIABETES MELLITUS; DIABETIC DIET; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GLUCOSE BLOOD LEVEL; GLUCOSURIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; KINESIOTHERAPY; LABORATORY TEST; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; METABOLIC DISORDER; METABOLIC SYNDROME X; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PATIENT MONITORING; PRACTICE GUIDELINE; REVIEW; TREATMENT CONTRAINDICATION; TREATMENT INDICATION;

EID: 34250628465     PISSN: 17301270     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (15)

1. Behrens G.M. i wsp.: Impaired glucose phosphorylation and transport in sceletal muscle cause insulin resistance in HIV-1-infected patients with lipodystrophy. Journal of Clinical Investigations 2002, 110, 1319-1327.
2. Carr A. i wsp.: Diagnosis. prediction, and natural course of HIV-I protease-inhibitor associated lipodystrophy, hyperlipidaemia and diabetes mellitus: a cohort study. Lancet 1999, 353(9170), 2093.
3. Dubé M.P. i wsp.: Protease inhibitor-associated hyperglycaemia. Lancet 1997, 350, 713.
4. Eastone J.A., Decker C.F.: New-onset diabetes mellitus associated with use of protease inhibitor. Ann. Intern. Med. 1997, 127, 948.
5. Garg A.: Aquired and Inherited Lipodystrophies. N. Engl. J. Med. 2004, 350, 1220.
6. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome 2005. www.idf.org
7. Lumpkin M.M.: Reports of diabetes and hyperglycemia in patients receiving protease inhibitors for the treatment of human immunodeficiency virus (HIV). Food and Drug Administration, 11.06.1997.
8. Mulligan K. i wsp.: Hyperlipidemia insulin resistance are induced by protease inhibitors independent of changes in body composition in patients mth HIV u6ction. J. Acquir. Immune. Defic. Syndr. 2000, 23(1), 35.
9. Murata H., Hruz P.W., Mueckler M.: The mechanisms of insulin resistance cused by HIV protease inhibitor therapy. J. Biol. Chem. 2000, 275 (27), 20251.
10. Panel on Clinical Practices for Treatment of HIV Infection (DHHS). Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, October 6, 2005. http://AIDSinfo.nih.gov
11. Tsiodras S. et al.: Effects of protease inhibitors on hyperglycaemia. hyperlipidaemia, and lipodystrophy. A 5-year cohort study. Archives of Internal Medicine 2000, 160, 2050.
12. Viraben R., Aquilina C.: Indinavir-associated lipodystrophy. AIDS 1998, 12, F37.
13. Visnegarwala F., Krause K.L., Musher D.M.: Severe diabetes associated with protease inhibitor therapy. Ann. Intern. Med. 1997, 127, 947.
14. Yarasheski K.E.: 3rd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Ateny, Grecja, 2001, abstr. 6
15. Zalecenia kliniczne dotyczace postepowania u chorych na cukrzyce. Stanowisko Polskiego Towarzystwa Diabetologicznego 2006. Medycyna Praktyczna 2006, 3(181), 111.